Status:
UNKNOWN
Role of Senescence in the Development of Endometrial Cancer
Lead Sponsor:
CHU de Reims
Conditions:
Endometrial Hyperplasia and Endometrial Cancers
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Several molecular studies showed chromosomal alterations in patients with endometrial cancer, with gains in 1q, 19p, 19q, 8q, 10q and 10p and loss of 4q, 16q and 18q. Several genes of interest have be...
Detailed Description
make a pangenomic investigation of genetic abnormalities in atypical endometrial hyperplasia and endometrial cancers.
Eligibility Criteria
Inclusion
- patient with endometrial hyperplasia or endometrial cancer
- patient consenting to participate to the study
- patient enrolled in the national healthcare insurance program
- patient older than 18 years
Exclusion
- \- patient with neoadjuvant chemotherapy or radiotherapy prior to surgery
Key Trial Info
Start Date :
October 16 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 16 2020
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT03338985
Start Date
October 16 2017
End Date
April 16 2020
Last Update
January 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Damien JOLLY
Reims, France